726.21 USD
+33.63 (+4.86%)
727.5 USD
+1.29 (+0.18%)
We assign a fundamental rating of 6 out of 10 to REGN. REGN was compared to 531 industry peers in the Biotechnology industry. REGN gets an excellent profitability rating and is at the same time showing great financial health properties. REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.40%, REGN belongs to the top of the industry, outperforming 94.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.79%, REGN belongs to the top of the industry, outperforming 94.73% of the companies in the same industry.
REGN has a Return On Invested Capital of 8.69%. This is amongst the best in the industry. REGN outperforms 94.16% of its industry peers.
REGN had an Average Return On Invested Capital over the past 3 years of 12.44%. This is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN has a Profit Margin of 32.13%. This is amongst the best in the industry. REGN outperforms 96.42% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
With an excellent Operating Margin value of 27.61%, REGN belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
REGN's Operating Margin has declined in the last couple of years.
REGN has a better Gross Margin (86.28%) than 88.70% of its industry peers.
In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
The number of shares outstanding for REGN has been reduced compared to 5 years ago.
Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.28 indicates that REGN is not in any danger for bankruptcy at the moment.
REGN has a Altman-Z score of 7.28. This is in the better half of the industry: REGN outperforms 77.59% of its industry peers.
REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
REGN has a better Debt to FCF ratio (0.70) than 94.54% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
REGN has a worse Debt to Equity ratio (0.09) than 63.28% of its industry peers.
Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.28 |
ROIC/WACC1.01
WACC8.57%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Current ratio (4.06) which is in line with its industry peers.
A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.51, REGN is in line with its industry, outperforming 42.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The earnings per share for REGN have decreased by -0.92% in the last year.
Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 5.63% on average per year.
EPS Next Y-3.71%
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
EPS Next 5Y6.38%
Revenue Next Year0.28%
Revenue Next 2Y2.84%
Revenue Next 3Y5.1%
Revenue Next 5Y5.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.13 indicates a correct valuation of REGN.
Based on the Price/Earnings ratio, REGN is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.59.
A Price/Forward Earnings ratio of 16.08 indicates a correct valuation of REGN.
Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 96.05% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.80. REGN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.13 | ||
| Fwd PE | 16.08 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 94.92% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.67 | ||
| EV/EBITDA | 14.5 |
4.3 Compensation for Growth
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.23
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
5. Dividend
5.1 Amount
With a yearly dividend of 0.49%, REGN is not a good candidate for dividend investing.
REGN's Dividend Yield is rather good when compared to the industry average which is at 66.57. REGN pays more dividend than 98.31% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.49% |
5.2 History
REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
726.21
+33.63 (+4.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.98%
Inst Owner Change-0.48%
Ins Owners1.91%
Ins Owner Change0.24%
Market Cap76.32B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80
Price Target796.01 (9.61%)
Short Float %2.81%
Short Ratio2.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.49% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)6.45%
PT rev (3m)6.52%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)16.14%
EPS NY rev (1m)2.79%
EPS NY rev (3m)9.97%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)4.32%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)2.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.13 | ||
| Fwd PE | 16.08 | ||
| P/S | 5.36 | ||
| P/FCF | 19.67 | ||
| P/OCF | 15.05 | ||
| P/B | 2.47 | ||
| P/tB | 2.58 | ||
| EV/EBITDA | 14.5 |
EPS(TTM)45.01
EY6.2%
EPS(NY)45.16
Fwd EY6.22%
FCF(TTM)36.93
FCFY5.08%
OCF(TTM)48.25
OCFY6.64%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.23
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.28 |
F-Score5
WACC8.57%
ROIC/WACC1.01
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.71%
EPS Next 2Y-0.53%
EPS Next 3Y6.11%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.28%
Revenue Next 2Y2.84%
Revenue Next 3Y5.1%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-4.04%
EBIT Next 3Y6.12%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -3.71% in the next year.